Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CT-011 Alone or with DC/RCC Fusion Vaccine in Renal Cell Carcinoma
NCT01441765Phase 2Terminated
- Sponsor
- Beth Israel Deaconess Medical Center
- Start
- Nov 2011
- Primary completion
- Jul 2016
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of pidilizumab in renal cell carcinoma (RCC), sponsored by Beth Israel Deaconess Medical Center. Started Nov 2011; status: terminated.
02
Drugs
pidilizumab
03
Conditions
renal cell carcinoma (RCC)
Beyond the preview
Go deeper on NCT01441765.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01441765.